About
Boris Djordjevic is a longevity-biotech entrepreneur best known as founder and CEO of 199 Biotechnologies and founder of 199 Longevity/199 Longevity Clinic. Public materials tie him to cellular reprogramming, senolytics, diagnostics, and preventive medicine, and ARDD conference profiles position him as a visible operator in the longevity ecosystem. A 2025 PubMed-listed paper also affiliates him with University College London.
Areas of interest
longevitybiotechnologyaging researchepigenetic reprogrammingcancer therapeuticssenolyticsdiagnosticspreventive medicinehealthspanAI